A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Schuetz, C Andy ^a   Alperin, Peter ^a   Guda, Swathi ^a   van Herick, Andrew ^a   Cariou, Bertrand ^b   Eddy, David ^a   Gumprecht, Janusz ^c   Nicolucci, Antonio ^d   Schwarz, Peter ^e   Wareham, Nick J ^f   Witte, Daniel R ^g   Smith, Ulf ^h  

^a Archimedes Inc   (United States)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d Consorzio Mario Negri Sud ^*  (Italy)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g STENO DIABETES CENTER   (Denmark)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARCHIMEDES MODEL; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; EUROPE; FRANCE; GERMANY; HEALTH CARE; HEALTH CARE COST; HEALTH CHECK; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; ITALY; LIFESTYLE MODIFICATION; MATHEMATICAL MODEL; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLAND; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM; SCREENING; SIMULATION; SMOKING; UNITED KINGDOM; VASCULAR DISEASE;

ADULT; AGED; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; VASCULAR DISEASES;

EID: 84880258276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066454     Document Type: Article

References (35)

1. World Health Organization (2004) The atlas of heart disease and stroke. World Health Organization. Available: http://www.who.int/cardiovascular_diseases/resources/atlas/en/. Accessed 2012 Nov 13.
2. Kanavos P, van den Aardweg S, Schurer W (2012) Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics.
3. Anand SS, Yusuf S, (2011) Stemming the global tsunami of cardiovascular disease. Lancet 377: 529-532.
4. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, et al. (2003) Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 26: 2604-2608.
5. Schwarz PE, Greaves CJ, Lindstrom J, Yates T, Davies MJ, (2012) Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 8: 363-373.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 360: 1903-1913.
7. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet 370: 1829-1839.
8. Davies M, Khunti K, Chauhan U, Stribling B, Goyder E, et al. (2008) The handbook for vascular risk assessment, risk reduction and risk management. UK National Screening Committee. Leicester: BMJ Publishing Group.
9. NHS Health Check Programme (2009) Putting Prevention First - NHS Health Check: Vascular Risk Assessment and Management Best Practice Guidance. London:Department of Health.
10. Department of Health (2008) Economic Modelling for Vascular Checks. In: Health Do, editor. London: Department of Health.
11. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, et al. (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375: 1365-1374.
12. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, et al. (2008) Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ (Clinical research ed) 336: 1180-1185.
13. Eddy DM, Schlessinger L, (2003) Archimedes: a trial-validated model of diabetes. Diabetes Care 26: 3093-3101.
14. Eddy DM, Schlessinger L, Kahn R, (2005) Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143: 251-264.
15. Archimedes model web site. Available: www.archimedesmodel.com. Accessed 2012 Nov 13.
16. Eddy DM, Schlessinger L, (2003) Validation of the archimedes diabetes model. Diabetes Care 26: 3102-3110.
17. Mount Hood 4 Modeling Group (2007) Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30: 1638-1646.
18. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
19. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data 1999-2008. Available: http://www.cdc.gov/nchs/nhanes.htm. Accessed 2012 Nov 13.
20. International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32: 1327-1334.
21. American Diabetes Association, (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34Suppl 1: S62-69.
22. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203.
23. Joint National Committee on Prevention D, Evaluation, and Treatment of High Blood Pressure (2003) JNC 7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. In: National Institutes of Health N, editor. NIH Publication, US Department of Health and Human Services.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
25. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239.
26. Lindstrom J, Tuomilehto J, (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26: 725-731.
27. Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ, (2008) A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. Family Practice 25: 191-196.
28. Tsai AG, Wadden TA, (2005) Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States. Annals of Internal Medicine 142: 56-66.
29. Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, et al. (2011) Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet 378: 1485-1492.
30. Lader D (2007) Omnibus Survey Report No. 32: Smoking-related Behaviour and Attitudes, 2006. Newport: Office for National Statistics. 16 p.
31. Ferguson J, Bauld L, Chesterman J, Judge K, (2005) The English smoking treatment services: one-year outcomes. Addiction 100Suppl 2: 59-69.
32. Altman DG, Andersen PK, (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319: 1492-1495.
33. Sullivan PW, Ghushchyan V, (2006) Preference-Based EQ-5D index scores for chronic conditions in the United States. Medical decision making: an international journal of the Society for Medical Decision Making 26: 410-420.
34. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, et al. (2002) Valuing health-related quality of life in diabetes. Diabetes Care 25: 2238-2243.
35. The Danish Diabetes Association website (nd) Treatment goals. Available: http://www.diabetes.dk/Rundt_om_diabetes/Behandlingskvalitet/Behandlingsmaal.aspx. Accessed 2013 Apr 19.